Business Wire
07 Jul 2026, 12:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
bioAffinity Technology reports year-over-year commercial sales growth of over 200% for its CyPath® Lung diagnostic. — Triple-digit revenue growth in a core product suggests strong market adoption and potential for significant near-term scaling.
+0.60Which stocks this story touches
The company reported significant growth in commercial sales for its CyPath Lung diagnostic.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
1h ago
